PatientID: NC798-1997

Okitobba 06, 2023

Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence	
PI	ATV	$^{ m HR}$		
	DRV	$_{ m LR}$		
	FPV	HR	I54V;V82F;L90M;G73C	
	IDV	$^{ m HR}$		
	LPV	HR		
	NFV	HR		
	SQV	HR		
	TPV	LR		
NRTI	ABC	HR		
	AZT	$^{ m HR}$		
	D4T	$^{ m HR}$		
	DDI	$_{ m HR}$	L210WL;M41L;M184V;T215Y	
	FTC	$_{ m HR}$		
	LMV	$_{ m HR}$		
	TDF	IR		
NNRTI	DOR	${f S}$		
	EFV	${f S}$		
	ETR	${f S}$		
	NVP	${f S}$		
	RPV	${f S}$		

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
	G73S/T/C/A are common non-polymorphic accessory mutations selected primarily by
	most PIs. They are associated with minimally reduced susceptibility to each of the PIs.
	I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to
	each of the PIs except DRV.
PI	L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to ATV and to
	a lesser extent LPV.
	V82F is a nonpolymorphic mutation selected primarily by IDV and LPV. It reduces LPV
	and DRV susceptibility.
	L210W is a TAM that usually occurs in combination with M41L and T215Y. The
	combination of M41, L210W and T215Y causes high-level resistance to AZT and
	intermediate resistance to ABC and TDF.
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to
	continued treatment with 3TC or FTC because they increase susceptibility to AZT and
	TDF and are associated with clinically significant reductions in HIV-1 replication.

NRTI	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility. T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.
NNRTI	
INSTI	